Nu-Medopa en es it fr

Nu-Medopa Brand names, Nu-Medopa Analogs

Nu-Medopa Brand Names Mixture

  • No information avaliable

Nu-Medopa Chemical_Formula


Nu-Medopa RX_link

Nu-Medopa fda sheet

Nu-Medopa FDA

Nu-Medopa msds (material safety sheet)

Nu-Medopa MSDS

Nu-Medopa Synthesis Reference

No information avaliable

Nu-Medopa Molecular Weight

1270.28 g/mol

Nu-Medopa Melting Point

No information avaliable

Nu-Medopa H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Nu-Medopa State


Nu-Medopa LogP

No information avaliable

Nu-Medopa Dosage Forms

Powder for solution (for injection)

Nu-Medopa Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Nu-Medopa Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Nu-Medopa Absorption

No information avaliable

Nu-Medopa side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Nu-Medopa Patient Information

No information avaliable

Nu-Medopa Organisms Affected

Aspergillis, Candida and other fungi